- Home
- BLW vs REPL Comparison
BLW vs REPL Comparison
Compare BLW & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLW | REPL |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.3M | 454.6M |
| IPO Year | 2003 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BLW | REPL |
|---|---|---|
| Price | $12.49 | $14.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | 128.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.06 | $1.50 |
| 52 Week High | $14.25 | $16.33 |
Technical Indicators
Market Signals| Indicator | BLW | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 54.67 |
| Support Level | $12.21 | $13.81 |
| Resistance Level | $12.81 | $15.71 |
| Average True Range (ATR) | 0.12 | 0.78 |
| MACD | -0.03 | -0.21 |
| Stochastic Oscillator | 14.29 | 39.68 |
Price Performance
Historical ComparisonAbout BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a closed-end management investment company. Its investment objective is to provide current income and capital appreciation.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.